Clarivate Plc Stock Price, News & Analysis

Clarivate (NYSE: CLVT) has been selected by the National and University Library in Zagreb (NSK) to provide its unified library services and discovery platform. The implementation includes Ex Libris Alma and Ex Libris Primo solutions, which will serve as a modern, unified library system across Croatia's academic and research institutions.

The cloud-based subscription service will be implemented in nine universities and 82 academic and research libraries throughout Croatia. This strategic project, part of the e-Universities initiative, is financed through the National Recovery and Resilience Plan 2021-2026. The implementation aims to streamline existing infrastructure of multiple library systems and data formats, while promoting Croatia's cultural and scientific heritage.

Clarivate (NYSE:CLVT) has published a new e-book analyzing breakthroughs in the pulsed field ablation (PFA) market for atrial fibrillation treatment. PFA technology uses high-voltage microsecond electrical pulses instead of thermal energy, offering safer and more effective procedures compared to traditional methods.

The report highlights significant market growth projections, with PFA expected to grow from $300 million (5% market share) in 2023 to $8 billion (70% market share) by 2028. Key developments include Johnson & Johnson's VARIPULSE FDA approval in November, though its U.S. rollout was paused due to safety concerns. Abbott Laboratories is anticipated to receive FDA approval by mid-2026.

International markets show strong adoption, particularly in Asia Pacific, where the market is projected to exceed $1 billion in 3-5 years, with Japan alone potentially reaching $300 million by 2028.

Clarivate (NYSE:CLVT) has released a report identifying the top 50 universities driving global innovation through academic research and patent citations. The study, leveraging data from Web of Science and Derwent databases, reveals how knowledge flows between academia and industry across different regions.

Key findings show these universities are spread across eleven countries, with U.S. institutions dominating the top positions. Harvard University leads in research output volume, while MIT demonstrates exceptional research-to-innovation translation despite smaller publication numbers. The report identifies strong regional citation patterns, with Eastern Asian and European companies primarily citing local academic research, while U.S. research maintains global influence.

Notable insights include that five organizations - Roche, Johnson & Johnson, CNRS, Samsung Electronics, and Siemens - account for 51% of citations from top innovations to academic research. The United Kingdom shows diverse international influence, often bridging regional research gaps. The report aims to help stakeholders make informed decisions about research partnerships, knowledge transfer strategies, and innovation investments.

The British Library has selected Clarivate (NYSE:CLVT) to provide its library services and discovery platforms, implementing Alma, Primo VE, and Rapido solutions. This decision builds upon a 20-year partnership and aims to create a more cohesive, streamlined, and secure experience.

The British Library, one of the world's largest libraries with a collection of 170 million items, will become the 43rd National and State library globally to adopt Alma. The implementation will unify platform operations, improve user experience, and enhance future services. The Rapido system will be used to streamline interlibrary loan processes, supporting resource sharing within the academic and research community.

Clarivate Plc (NYSE: CLVT) has announced it will release its fourth quarter and full year 2024 financial results before market opening on Wednesday, February 19, 2025. The company will make the press release and earnings supplement with financial information available on their investor website. Following the release, Clarivate will host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results.

BioWorld, published by Clarivate (NYSE:CLVT), has released its comprehensive 2024 Year in Review series analyzing key developments in biopharma, medtech, and scientific innovation. The report highlights significant therapeutic breakthroughs in psychiatry, oncology, women's health, and infectious diseases.

Key findings include the industry's resilience despite challenges, with biopharma financing and deal values rebounding amid over 18,000 job losses. Notable developments include GLP-1 receptor agonists' expansion into new therapeutic areas, significant progress in AI-driven medtech in APAC, and breakthrough cancer research data from trials like Checkmate-067 and Keynote-006.

The report also covers important regulatory changes, including the end of the Chevron doctrine affecting agency authority, and Medicare coverage challenges for emerging technologies. European biotech funding showed improvement in 2024, particularly in antibody-drug conjugates (ADCs) and CNS treatments.

Clarivate (NYSE:CLVT) has launched DRG Fusion, a new analytics platform designed to support commercial analytics in life sciences. The platform integrates real-world data from medical and pharmacy claims to help biopharma and medtech organizations optimize their commercial strategies.

The platform features modular data analytics products with configurable dashboards supporting patient journey analysis, commercial targeting, market access optimization, and patient segmentation. Fusion streamlines data management by providing ready-made visuals and tables to accelerate commercial decisions.

The company plans to introduce AI-driven and self-service features to Fusion in 2025, demonstrating its commitment to delivering user-centric solutions for healthcare challenges.

Clarivate (NYSE:CLVT) has released its twelfth annual Drugs to Watch™ report, identifying 11 potential blockbuster therapies expected to achieve significant market success or transform treatment paradigms by 2030. The report highlights innovations in obesity, oncology, and gene therapy, powered by Clarivate's Cortellis intelligence suite.

Key featured drugs include AWIQLI® (first weekly insulin), CagriSema (obesity treatment), COBENFY™ (schizophrenia therapy), and EBGLYSS™ (atopic dermatitis treatment). The report also analyzes the chronic disease market in Mainland China and explores industry trends including AI integration, radiopharmaceutical theranostics, and the growing importance of real-world data in healthcare decisions.

The analysis demonstrates Clarivate's strong track record, with 12 out of 13 molecules identified in last year's report already approved and launched.

Clarivate (NYSE:CLVT) has announced a new $500 million share repurchase program for its outstanding ordinary shares, effective from January 1, 2025, through December 31, 2026. This program replaces the current one ending December 31, 2024, under which the company repurchased $300 million of shares, including $200 million in Q3-Q4 2024.

Additionally, Clarivate has prepaid $75 million of term-loan debt in Q4, bringing total 2024 prepayments to $133 million. The new buyback program, part of the company's Value Creation Plan, allows for open-market purchases through various methods, including Rule 10b5-1 trading plans, subject to market conditions and regulatory requirements.